Quince Therapeutics, Inc. QNCX 深 滬
等待開盤 01-29 09:30:00 美东时间
3.18
-0.130
-3.93%
華盛通- 最 高3.35
- 今 開3.34
- 成交量 120.21万股
- 最 低 3.15
- 昨 收 3.31
- 總市值 1.71亿
- 52周最高 4.5499
- 市盈率 靜 --
- 換手率 2.24%
- 52周最低 0.7203
- 委 比 -18.59%
- 總股本 5371.38万
- 歷史最高 121.98
- 量 比 1.09
- 振 幅 6.04%
- 歷史最低 0.5116
- 每 手 1
- 風險率 0.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Quince Therapeutics Announced The Poster Presentation From The Long-term Treatment Of Children With Ataxia-Telangiectasia At The British Paediatric Neurology Association 2026 Annual Meeting; Long-term Treatment With eDSP In Children With A-T Was Associated With Stable Growth And Metabolic Parameters Without Indications Of Corticosteroid-Related Toxicities
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation of
今天 05:30
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
Quince Therapeutics Says Last Patient Completed Last Visit In Pivotal Phase 3 NEAT Clinical Trial Of eDSP, In Patients With Ataxia-Telangiectasia; Expects To Report Topline Results From In Q1 2026
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that the last patient has
2025-12-15 21:07
Catalyst Watch: Holiday shopping data, Amazon event, and Salesforce earnings
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - December ...
2025-11-29 02:30
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
Quince Therapeutics shares are trading higher after the company said an independent data and safety monitoring board found no safety concerns in its Phase 3 NEAT trial and recommended the study continue without changes.
Quince Therapeutics shares are trading higher after the company said an indepen...
2025-11-11 05:21
Quince Therapeutics Announces Poster Presentation Of Patient-Reported Walking Capacity In Children With Ataxia-Telangiectasia At 54th CNS Annual Meeting
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation of
2025-10-10 04:08
美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
2025-09-29 09:15
Quince Therapeutics Amends Credit Facility Agreement
Quince Therapeutics ( ($QNCX) ) has provided an update. On September 25, 2025, ...
2025-09-27 05:16
Quince Therapeutics Publishes Advanced PK Modeling Study Of Phase 3 Asset eDSP In A-T Patients And Healthy Adults In ASCPT Journal PSP
Quince Therapeutics, Inc.
2025-09-26 04:07
